Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
Clin Cancer Res
    May 2024
  1. REKHTMAN N
    All That Is Small Is Not a Small-Cell Carcinoma: Thoracic SMARCA4-Deficient Undifferentiated Tumors Masquerading as SCLC.
    Clin Cancer Res. 2024;30:1708-1711.
    >> Share

  2. MARINIELLO A, Nasti TH, Chang DY, Hashimoto M, et al
    Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade.
    Clin Cancer Res. 2024;30:1833-1845.
    >> Share

    April 2024
  3. ZHOU R, Liu F, Zhang H, Wang D, et al
    Fraction dose escalation of hypofractionated radiotherapy with concurrent chemotherapy and subsequent consolidation immunotherapy in locally advanced non-small cell lung cancer: a phase 1 study.
    Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-23-3600.
    >> Share

  4. ZUGAZAGOITIA J, Osma H, Baena J, Ucero AC, et al
    Facts and hopes on cancer immunotherapy for small cell lung cancer.
    Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-1159.
    >> Share

  5. PERESSINI M, Garcia-Campelo R, Massuti B, Marti C, et al
    Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer.
    Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-24-0104.
    >> Share

  6. GRAZINI U, Markovets A, Ireland L, O'Neill D, et al
    Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven Non-Small-Cell-Lung-Cancer with PIK3CA/PTEN alterations.
    Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-2540.
    >> Share

  7. OH HJ, Bae SC, Oh IJ, Park CK, et al
    Nicotinamide in Combination with EGFR-TKIs for the Treatment of Stage IV Lung Adenocarcinoma with EGFR Mutations: A Randomized Double-Blind (Phase IIb) Trial.
    Clin Cancer Res. 2024;30:1478-1487.
    >> Share

  8. LEE EJ, Oh SY, Lee YW, Kim JY, et al
    Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC.
    Clin Cancer Res. 2024;30:1582-1594.
    >> Share

  9. SINGH AK, Lewis CD, Boas CAWV, Diebolder P, et al
    Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library.
    Clin Cancer Res. 2024;30:1293-1306.
    >> Share

  10. VAIDYA P, Cohen EEW
    Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence.
    Clin Cancer Res. 2024;30:1232-1239.
    >> Share

    February 2024
  11. ZHOU I, Plana D, Palmer AC
    Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial.
    Clin Cancer Res. 2024;30:786-792.
    >> Share

  12. KASI PM, Lee JK, Pasquina LW, Decker B, et al
    Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types.
    Clin Cancer Res. 2024;30:836-848.
    >> Share

  13. WEI D, Wang L, Zuo X, Maitra A, et al
    A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.
    Clin Cancer Res. 2024;30:655-662.
    >> Share

  14. WANG H, Chen Y, Wang X, Huang B, et al
    Germline mutations of Holliday junction resolvase genes in multiple primary malignancies involving lung cancer lead to PARP inhibitor sensitization.
    Clin Cancer Res. 2024 Feb 13. doi: 10.1158/1078-0432.CCR-22-3300.
    >> Share

  15. VAN DE HAAR J, Mankor JM, Hummelink K, Monkhorst K, et al
    Combining genomic biomarkers to guide immunotherapy in non-small cell lung cancer.
    Clin Cancer Res. 2024 Feb 1. doi: 10.1158/1078-0432.CCR-23-4027.
    >> Share

  16. LAKHANI NJ, Rasco D, Wang H, Men L, et al
    First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors.
    Clin Cancer Res. 2024;30:506-521.
    >> Share

    January 2024
  17. PARRA ER, Zhang J, Duose DY, Gonzalez-Kozlova E, et al
    Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial.
    Clin Cancer Res. 2024 Jan 26. doi: 10.1158/1078-0432.CCR-23-0251.
    >> Share

  18. GUAN S, Chen X, Wei Y, Wang F, et al
    Germline USP36 mutation confers resistance to EGFR-TKIs by upregulating MLLT3 expression in non-small cell lung cancer patients.
    Clin Cancer Res. 2024 Jan 23. doi: 10.1158/1078-0432.CCR-23-2357.
    >> Share

  19. KESARI S, Wagle N, Carrillo JA, Sharma A, et al
    Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma.
    Clin Cancer Res. 2024;30:323-333.
    >> Share

  20. NG J, Cai L, Girard L, Prall OWJ, et al
    Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies.
    Clin Cancer Res. 2024 Jan 5:OF1-OF13. doi: 10.1158/1078-0432.CCR-23-2360.
    >> Share

  21. NAKAMICHI S, Kubota K, Misumi T, Kondo T, et al
    Phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non-small-cell lung cancer: TORG1937 (DATE study).
    Clin Cancer Res. 2024 Jan 2. doi: 10.1158/1078-0432.CCR-23-2568.
    >> Share

    December 2023
  22. LOPEZ DE RODAS M, Wang Y, Peng G, Gu J, et al
    Objective analysis and clinical significance of the spatial tumor infiltrating lymphocyte patterns in non-small cell lung cancer (NSCLC).
    Clin Cancer Res. 2023 Dec 21. doi: 10.1158/1078-0432.CCR-23-2457.
    >> Share

  23. PASSIGLIA F, Righi L, Bironzo P, Listi A, et al
    Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer harboring HRR mutations: interim results of the UNITO-001 phase 2 prospective trial.
    Clin Cancer Res. 2023 Dec 18. doi: 10.1158/1078-0432.CCR-23-2431.
    >> Share

  24. BOUMELHA J, Molina-Arcas M, Downward J
    Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.
    Clin Cancer Res. 2023;29:5012-5020.
    >> Share

  25. HUMMELINK K, Tissier R, Bosch LJW, Krijgsman O, et al
    A dysfunctional T cell gene signature for predicting non-response to PD-1 blockade in non-small cell lung cancer that is suitable for routine clinical diagnostics.
    Clin Cancer Res. 2023 Dec 13. doi: 10.1158/1078-0432.CCR-23-1061.
    >> Share

  26. ROLFO C, Russo A
    In search of lost biomarker for immunotherapy in small-cell lung cancer.
    Clin Cancer Res. 2023 Dec 12. doi: 10.1158/1078-0432.CCR-23-3087.
    >> Share

  27. BESSEDE A, Peyraud F, Besse B, Cousin S, et al
    TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.
    Clin Cancer Res. 2023 Dec 1. doi: 10.1158/1078-0432.CCR-23-2566.
    >> Share

  28. VOKES NI, Galan Cobo A, Fernandez-Chas M, Molkentine D, et al
    ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC.
    Clin Cancer Res. 2023;29:4958-4972.
    >> Share

    November 2023
  29. MURRAY JC, Sivapalan L, Hummelink K, Balan A, et al
    Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer.
    Clin Cancer Res. 2023 Nov 8. doi: 10.1158/1078-0432.CCR-23-1469.
    >> Share

    October 2023
  30. HERBST RS, Blanke CD, Sigal EV
    Novel Approach to Accelerate Lung Cancer Research: LungMap and the Potential of Public-Private Partnerships.
    Clin Cancer Res. 2023 Oct 30. doi: 10.1158/1078-0432.CCR-23-2690.
    >> Share

  31. PAZ-ARES L, Garassino MC, Chen Y, Reinmuth N, et al
    Durvalumab +/- tremelimumab + platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): outcomes by PD-L1 expression and tissue tumor mutational burden.
    Clin Cancer Res. 2023 Oct 6. doi: 10.1158/1078-0432.CCR-23-1689.
    >> Share

    September 2023
  32. BESSEDE A, Peyraud F, Le Moulec S, Cousin S, et al
    Upregulation of Indoleamine 2,3-dioxygenase 1 in tumor cells and tertiary lymphoid structures is a hallmark of inflamed non-small cell lung cancer.
    Clin Cancer Res. 2023 Sep 26. doi: 10.1158/1078-0432.CCR-23-1928.
    >> Share

  33. DIMOU A
    Time to Think About Human Leukocyte Antigen-Based Diagnostics in Lung Cancer?
    Clin Cancer Res. 2023 Sep 26. doi: 10.1158/1078-0432.CCR-23-2152.
    >> Share

  34. SOLTA A, Boettiger K, Kovacs I, Lang C, et al
    Entinostat enhances the efficacy of chemotherapy in small cell lung cancer through S-phase arrest and decreased base excision repair.
    Clin Cancer Res. 2023 Sep 19. doi: 10.1158/1078-0432.CCR-23-1795.
    >> Share

  35. CANTOR DJ, Aggarwal C
    Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond.
    Clin Cancer Res. 2023;29:3563-3565.
    >> Share

  36. DUKE ES, Bradford D, Marcovitz M, Amatya AK, et al
    FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.
    Clin Cancer Res. 2023;29:3573-3578.
    >> Share

  37. ABEL ML, Takahashi N, Peer C, Redon CE, et al
    Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial.
    Clin Cancer Res. 2023;29:3603-3611.
    >> Share

  38. PELLINI B, Madison RW, Childress M, Miller ST, et al
    Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2023 Sep 13. doi: 10.1158/1078-0432.CCR-23-1578.
    >> Share

    August 2023
  39. ZHOU X, Zhou L, Yao Z, Huang M, et al
    Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small-Cell Lung Cancer Patients.
    Clin Cancer Res. 2023 Aug 15:CCR-23-0315. doi: 10.1158/1078-0432.CCR-23-0315.
    >> Share

  40. KREBS MG, Popat S
    RETaliation-Tackling Rare Resistance Alterations to Osimertinib.
    Clin Cancer Res. 2023;29:2951-2953.
    >> Share

  41. ROTOW J, Patel JD, Hanley MP, Yu H, et al
    Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers.
    Clin Cancer Res. 2023;29:2979-2987.
    >> Share

  42. MATHIEU LN, Larkins E, Sinha AK, Mishra-Kalyani PS, et al
    FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC.
    Clin Cancer Res. 2023;29:2973-2978.
    >> Share

  43. VALENCIA K, Montuenga LM, Calvo A
    Estrogen receptor and immune checkpoint inhibitors: new partners in lung cancer?
    Clin Cancer Res. 2023 Aug 7:CCR-23-1736. doi: 10.1158/1078-0432.CCR-23-1736.
    >> Share

    July 2023
  44. JIANG T, Jin Q, Wang J, Wu F, et al
    HLA-I evolutionary divergence confers response to PD-1 blockade plus chemotherapy in untreated advanced non-small-cell lung cancer.
    Clin Cancer Res. 2023 Jul 14:CCR-23-0604. doi: 10.1158/1078-0432.CCR-23-0604.
    >> Share

  45. CORTELLINI A, D'Alessio A, Cleary S, Buti S, et al
    Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer.
    Clin Cancer Res. 2023;29:2714-2724.
    >> Share

  46. THUMMALAPALLI R, Ricciuti B, Bandlamudi C, Muldoon D, et al
    Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.
    Clin Cancer Res. 2023 Jul 11:CCR-23-1207. doi: 10.1158/1078-0432.CCR-23-1207.
    >> Share

  47. COLLINS G, Stewart M, McKelvey B, Stires H, et al
    Breakthrough Therapy Designation Criteria Identify Drugs that Improve Clinical Outcomes for Patients: A Case for More Streamlined Coverage of Promising Therapies.
    Clin Cancer Res. 2023;29:2371-2374.
    >> Share

    June 2023
  48. CHAKRABORTY S, Coleman C, Manoj P, Demircioglu D, et al
    De novo and histologically transformed small cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways.
    Clin Cancer Res. 2023 Jun 29:CCR-23-0471. doi: 10.1158/1078-0432.CCR-23-0471.
    >> Share

  49. GRAY JE, Ahn MJ, Oxnard GR, Shepherd FA, et al
    Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.
    Clin Cancer Res. 2023 Jun 28:CCR-22-3146. doi: 10.1158/1078-0432.CCR-22-3146.
    >> Share

  50. KABRAJI S, Lin NU
    Keeping it in the family: HER3 as a target in brain metastases.
    Clin Cancer Res. 2023 Jun 12:CCR-23-1107. doi: 10.1158/1078-0432.CCR-23-1107.
    >> Share

  51. RAMKUMAR K, Tanimoto A, Della Corte CM, Stewart CA, et al
    Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer.
    Clin Cancer Res. 2023 Jun 8:CCR-23-0375. doi: 10.1158/1078-0432.CCR-23-0375.
    >> Share

  52. ANOBILE DP, Salaroglio IC, Tabbo F, La Vecchia S, et al
    Autocrine 17-beta-estradiol/estrogen receptor-alpha loop determines the response to immune-checkpoint inhibitors in non-small cell lung cancer.
    Clin Cancer Res. 2023 Jun 7:CCR-22-3949. doi: 10.1158/1078-0432.CCR-22-3949.
    >> Share

  53. PAWELETZ CP, Heavey GA, Kuang Y, Durlacher E, et al
    Early changes in circulating cell free KRAS G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients.
    Clin Cancer Res. 2023 Jun 6:CCR-23-0795. doi: 10.1158/1078-0432.CCR-23-0795.
    >> Share

    May 2023
  54. LIM SM, Fujino T, Kim C, Lee G, et al
    BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2023 May 30:CCR-22-3901. doi: 10.1158/1078-0432.CCR-22-3901.
    >> Share

  55. EISNER JR, Mayhew GM, Davison JM, Beebe KD, et al
    Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non-Small Cell Lung Cancer - The Piedmont Study.
    Clin Cancer Res. 2023 May 26:CCR-22-2558. doi: 10.1158/1078-0432.CCR-22-2558.
    >> Share

  56. GADGEEL SM, Miao J, Riess JW, Moon J, et al
    Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042).
    Clin Cancer Res. 2023 May 26:CCR-22-3947. doi: 10.1158/1078-0432.CCR-22-3947.
    >> Share

  57. BHATT A, Schabath MB, Hoogland AI, Jim HSL, et al
    Patient-Reported Outcomes as Inter-Radiographic Predictors of Response in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2023 May 26:CCR-23-0396. doi: 10.1158/1078-0432.CCR-23-0396.
    >> Share

  58. CHOUDHURY NJ, Lavery JA, Brown S, de Bruijn I, et al
    The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer.
    Clin Cancer Res. 2023 May 24:CCR-23-0580. doi: 10.1158/1078-0432.CCR-23-0580.
    >> Share

  59. LIAM CK, Ahmad AR, Hsia TC, Zhou J, et al
    Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis.
    Clin Cancer Res. 2023;29:1879-1886.
    >> Share

    April 2023
  60. RICCIUTI B, Elkrief A, Alessi J, Wang X, et al
    Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer.
    Clin Cancer Res. 2023 Apr 25:CCR-22-3413. doi: 10.1158/1078-0432.CCR-22-3413.
    >> Share

  61. PELLINI B, Chaudhuri AA
    ctDNA Monitoring for Small Cell Lung Cancer: Ready for Prime Time?
    Clin Cancer Res. 2023 Apr 25:OF1-OF3. doi: 10.1158/1078-0432.CCR-23-0420.
    >> Share

  62. BLAQUIER JB, Ortiz-Cuaran S, Ricciuti B, Mezquita L, et al
    Tackling osimertinib resistance in EGFR mutant non-small cell lung cancer.
    Clin Cancer Res. 2023 Apr 24:CCR-22-1912. doi: 10.1158/1078-0432.CCR-22-1912.
    >> Share

  63. SIVAPALAN L, Iams WT, Belcaid Z, Scott SC, et al
    Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer.
    Clin Cancer Res. 2023 Apr 18:OF1-OF14. doi: 10.1158/1078-0432.CCR-22-2242.
    >> Share

  64. JACOBSEN SKANDERUP A, Ang SF, Tan DSW
    Liquid Biopsies for Cancer Genotyping: Coming of Age?
    Clin Cancer Res. 2023;29:1381-1383.
    >> Share

  65. ELKRIEF A, Makhnin A, Moses KA, Ahn LS, et al
    Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas.
    Clin Cancer Res. 2023;29:1423-1428.
    >> Share

  66. TOMASICH E, Steindl A, Paiato C, Hatziioannou T, et al
    Frequent overexpression of HER3 in brain metastases from breast and lung cancer.
    Clin Cancer Res. 2023 Apr 10:CCR-23-0020. doi: 10.1158/1078-0432.CCR-23-0020.
    >> Share

  67. CHON K, Larkins E, Chatterjee S, Mishra-Kalyani PS, et al
    FDA Approval Summary: Amivantamab for the Treatment of patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
    Clin Cancer Res. 2023 Apr 6:CCR-22-3713. doi: 10.1158/1078-0432.CCR-22-3713.
    >> Share

  68. TUCKER ER, Jimenez I, Chen L, Bellini A, et al
    Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models.
    Clin Cancer Res. 2023;29:1317-1331.
    >> Share

  69. PATEL SA, Nilsson MB, Yang Y, Le X, et al
    IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC.
    Clin Cancer Res. 2023;29:1292-1304.
    >> Share

    March 2023
  70. XIA L, Yang Y, Chen W, Liu L, et al
    Perioperative ctDNA-Based MRD Detection in NSCLC-Response.
    Clin Cancer Res. 2023;29:1156.
    >> Share

  71. YU M, Ju L, Cao X
    Perioperative ctDNA-Based MRD Detection in NSCLC-Letter.
    Clin Cancer Res. 2023;29:1155.
    >> Share

  72. BRUNO R, Marchand M, Yoshida K, Chan P, et al
    Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.
    Clin Cancer Res. 2023;29:1047-1055.
    >> Share

  73. GRANT MJ, Aredo JV, Starrett JH, Stockhammer P, et al
    Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations.
    Clin Cancer Res. 2023 Mar 13:CCR-22-3497. doi: 10.1158/1078-0432.CCR-22-3497.
    >> Share

  74. GURSKA LM, Okabe R, Schurer A, Tong MM, et al
    Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.
    Clin Cancer Res. 2023;29:943-956.
    >> Share

    February 2023
  75. WILDSMITH S, Li W, Wu S, Stewart R, et al
    Tumor Mutational Burden as a Predictor of Survival With Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2023 Feb 20:CCR-22-2765. doi: 10.1158/1078-0432.CCR-22-2765.
    >> Share

  76. ROSNER S, Reuss JE, Zahurak M, Zhang J, et al
    Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2023;29:705-710.
    >> Share

  77. WIJETUNGA NA, Goglia AG, Weinhold N, Berger MF, et al
    Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases.
    Clin Cancer Res. 2023;29:775-783.
    >> Share

  78. OWEN DH, Benner B, Wei L, Sukrithan V, et al
    A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms.
    Clin Cancer Res. 2023;29:731-741.
    >> Share

  79. ROSNER S, Reuss JE, Zahurak M, Zhang J, et al
    Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2023 Feb 15:OF1-OF6. doi: 10.1158/1078-0432.CCR-22-2994.
    >> Share

  80. LEE HS, Jang HJ, Ramineni M, Wang DY, et al
    A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma.
    Clin Cancer Res. 2023;29:548-559.
    >> Share

  81. AUGUSTIN RC, Bao R, Luke JJ
    Old Dog, New Trick: A Tumor-Intrinsic Role for PD-1 in Chemoresistant Tumor Subclones.
    Clin Cancer Res. 2023;29:505-507.
    >> Share

  82. WANG J, Guo W, Wang X, Tang X, et al
    Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma.
    Clin Cancer Res. 2023;29:659-666.
    >> Share

    January 2023
  83. ZHANG Y, Tacheva-Grigorova SK, Sutton J, Melton Z, et al
    Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer.
    Clin Cancer Res. 2023 Jan 23:OF1-OF15. doi: 10.1158/1078-0432.CCR-22-2293.
    >> Share

  84. JONES R, Plummer R, Moreno V, Carter L, et al
    A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.
    Clin Cancer Res. 2023;29:331-340.
    >> Share

  85. OH SY, Lee YW, Lee EJ, Kim JH, et al
    Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC.
    Clin Cancer Res. 2023;29:221-232.
    >> Share

  86. WAINBERG ZA, Singh AS, Konecny GE, McCann KE, et al
    Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy.
    Clin Cancer Res. 2023;29:40-49.
    >> Share

    December 2022
  87. PALANKI R, Swingle KL, Mitchell MJ
    A (Controlled) Spill of IL2 for Localized Treatment of Mesothelioma.
    Clin Cancer Res. 2022;28:5010-5012.
    >> Share

  88. NASH AM, Aghlara-Fotovat S, Castillio B, Hernandez A, et al
    Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors.
    Clin Cancer Res. 2022;28:5121-5135.
    >> Share

    November 2022
  89. ANAGNOSTOU V, Luke JJ
    Quantitative Spatial Profiling of TILs as the Next Step beyond PD-L1 Testing for Immune Checkpoint Blockade.
    Clin Cancer Res. 2022;28:4835-4837.
    >> Share

  90. LIM EA, Bendell JC, Falchook GS, Bauer TM, et al
    Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
    Clin Cancer Res. 2022;28:4871-4884.
    >> Share

  91. HUMMELINK K, van der Noort V, Muller M, Schouten RD, et al
    PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC.
    Clin Cancer Res. 2022;28:4893-4906.
    >> Share

  92. POULIKAKOS PI, Sullivan RJ, Yaeger R
    Molecular Pathways and Mechanisms of BRAF in Cancer Therapy.
    Clin Cancer Res. 2022;28:4618-4628.
    >> Share

    October 2022
  93. BRAMAN N, Prasanna P, Bera K, Alilou M, et al
    Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple Cancers.
    Clin Cancer Res. 2022;28:4410-4424.
    >> Share

  94. SUGIMOTO A, Matsumoto S, Udagawa H, Itotani R, et al
    A large-scale prospective concordance study of plasma- and tissue-based next-generation targeted sequencing for advanced non-small cell lung cancer (LC-SCRUM-Liquid).
    Clin Cancer Res. 2022 Oct 6. pii: 709652. doi: 10.1158/1078-0432.CCR-22-1749.
    >> Share

  95. JUNG HA, Lim J, Choi YL, Lee SH, et al
    Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.
    Clin Cancer Res. 2022;28:4312-4321.
    >> Share

    September 2022
  96. ROCHIGNEUX P, Lisberg A, Garcia A, Granjeaud S, et al
    Mass cytometry reveals classical monocytes, NK cells and ICOS+ CD4+ T cells associated with pembrolizumab efficacy in lung cancer patients.
    Clin Cancer Res. 2022 Sep 27. pii: 709487. doi: 10.1158/1078-0432.CCR-22-1386.
    >> Share

  97. ROTOLO R, Leuci V, Donini C, Galvagno F, et al
    Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells.
    Clin Cancer Res. 2022 Sep 27. pii: 709485. doi: 10.1158/1078-0432.CCR-22-0761.
    >> Share

  98. DUKE ES, Stapleford L, Drezner N, Amatya AK, et al
    FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
    Clin Cancer Res. 2022 Sep 16. pii: 709236. doi: 10.1158/1078-0432.CCR-22-2072.
    >> Share

  99. GUIDRY K, Vasudevaraja V, Labbe K, Mohamed H, et al
    DNA Methylation Profiling Identifies Subgroups of Lung Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age, and Clinical Outcome.
    Clin Cancer Res. 2022;28:3824-3835.
    >> Share

  100. KENNEDY GT, Holt DE, Azari FS, Bernstein E, et al
    A Cathepsin-Targeted Quenched Activity-Based Probe Facilitates Enhanced Detection of Human Tumors during Resection.
    Clin Cancer Res. 2022;28:3729-3741.
    >> Share

  101. MACK PC, Miao J, Redman MW, Moon J, et al
    Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403).
    Clin Cancer Res. 2022;28:3752-3760.
    >> Share

  102. YAP TA, Gainor JF, Callahan MK, Falchook GS, et al
    First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
    Clin Cancer Res. 2022;28:3695-3708.
    >> Share

    August 2022
  103. MAHADEVAN NR, Sholl LM
    To Rb or Not to Rb: Uncovering Unique Subsets of Small Cell Lung Carcinoma.
    Clin Cancer Res. 2022 Aug 31. pii: 708945. doi: 10.1158/1078-0432.CCR-22-2187.
    >> Share

  104. TANIGUCHI Y, Shimokawa T, Takiguchi Y, Misumi T, et al
    A randomized comparison of nivolumab versus nivolumab + docetaxel for previously treated advanced or recurrent ICI-naive non-small-cell lung cancer: TORG1630.
    Clin Cancer Res. 2022 Aug 18. pii: 708059. doi: 10.1158/1078-0432.CCR-22-1687.
    >> Share

  105. OZCAN G, Singh M, Vredenburgh JJ
    Leptomeningeal Metastasis from Non-Small Cell Lung Cancer and Current Landscape of Treatments.
    Clin Cancer Res. 2022 Aug 16. pii: 707826. doi: 10.1158/1078-0432.CCR-22-1585.
    >> Share

  106. KIM TW, Burris HA, de Miguel Luken MJ, Pishvaian MJ, et al
    First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.
    Clin Cancer Res. 2022;28:3452-3463.
    >> Share

  107. HIATT JB, Sandborg H, Garrison SM, Arnold HU, et al
    Inhibition of LSD1 with bomedemstat sensitizes small cell lung cancer to immune checkpoint blockade and T cell killing.
    Clin Cancer Res. 2022 Aug 3. pii: 707373. doi: 10.1158/1078-0432.CCR-22-1128.
    >> Share

  108. WEI S, Gao X, Tang M, Li J, et al
    Perioperative ctDNA-Based MRD Detection in NSCLC- Letter.
    Clin Cancer Res. 2022;28:3400.
    >> Share

  109. XIA L, Chen W, Liu L
    Perioperative ctDNA-Based MRD Detection in NSCLC-Response.
    Clin Cancer Res. 2022;28:3401.
    >> Share

    July 2022
  110. HUNIHAN L, Zhao D, Lazowski H, Li M, et al
    RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition.
    Clin Cancer Res. 2022;28:3091-3103.
    >> Share

  111. BARLESI F, Tomasini P, Karimi M, Michiels S, et al
    Comprehensive genome profiling in patients with metastatic non-small cell lung cancer: the precision medicine phase 2 randomized SAFIR02-Lung trial.
    Clin Cancer Res. 2022 Jul 8. pii: 706925. doi: 10.1158/1078-0432.CCR-22-0371.
    >> Share

  112. FEBRES ALDANA CA, Chang JC, Ptashkin R, Wang Y, et al
    Rb tumor suppressor in small cell lung cancer: Combined genomic and immunohistochemical analysis with a description of a distinct Rb-proficient subset.
    Clin Cancer Res. 2022 Jul 6. pii: 706889. doi: 10.1158/1078-0432.CCR-22-1115.
    >> Share

    June 2022
  113. SCHOENFELD AJ, Rizvi HA, Memon D, Shaverdian N, et al
    Systemic and oligo-acquired resistance to PD-(L)1 blockade in lung cancer.
    Clin Cancer Res. 2022 Jun 29. pii: 705289. doi: 10.1158/1078-0432.CCR-22-0657.
    >> Share

  114. AKAMATSU H, Teraoka S, Takamori S, Miura S, et al
    Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L).
    Clin Cancer Res. 2022 Jun 28:OF1-OF7. doi: 10.1158/1078-0432.CCR-22-0602.
    >> Share

  115. YANG JC, Ohe Y, Chiu CH, Ou X, et al
    Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B).
    Clin Cancer Res. 2022 Jun 23:OF1-OF10. doi: 10.1158/1078-0432.CCR-21-4329.
    >> Share

  116. GUAN S, Chen X, Chen Y, Xie W, et al
    FOXM1 variant contributes to gefitinib resistance via activating wnt/beta-catenin signal pathway in non-small cell lung cancer patients.
    Clin Cancer Res. 2022 Jun 13. pii: 704872. doi: 10.1158/1078-0432.CCR-22-0791.
    >> Share

  117. MURCIANO-GOROFF YR, Harada G, Drilon A
    An Ascendant Challenge: Central Nervous System Metastases in ALK+ Lung Cancers.
    Clin Cancer Res. 2022;28:2477-2479.
    >> Share

  118. TAKEMOTO A, Takagi S, Ukaji T, Gyobu N, et al
    Targeting Podoplanin for the Treatment of Osteosarcoma.
    Clin Cancer Res. 2022;28:2633-2645.
    >> Share

  119. ROCHA P, Zhang J, Laza-Briviesca R, Cruz-Bermudez A, et al
    Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC.
    Clin Cancer Res. 2022;28:2461-2473.
    >> Share

  120. TSENG D, Gainor JF
    Searching for Synergy: Chemotherapy and Checkpoint Inhibitors.
    Clin Cancer Res. 2022;28:2206-2208.
    >> Share

  121. PATIL T, Bunn PA
    Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions?
    Clin Cancer Res. 2022;28:2204-2205.
    >> Share

  122. CHOUDHURY AD, Higano CS, de Bono JS, Cook N, et al
    A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kbeta/delta, in Patients with Advanced Solid Tumors.
    Clin Cancer Res. 2022;28:2257-2269.
    >> Share

  123. AKINBORO O, Larkins E, Pai-Scherf LH, Mathieu LN, et al
    FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC.
    Clin Cancer Res. 2022;28:2221-2228.
    >> Share

  124. JUNG HA, Park S, Choi YL, Lee SH, et al
    Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study.
    Clin Cancer Res. 2022;28:2321-2328.
    >> Share

    May 2022
  125. AKAMATSU H, Teraoka S, Takamori S, Miura S, et al
    Nivolumab retreatment in non-small cell lung cancer patients who responded to prior immune-checkpoint inhibitors and had ICI-free intervals (WJOG9616L).
    Clin Cancer Res. 2022 May 26. pii: 699251. doi: 10.1158/1078-0432.CCR-22-0602.
    >> Share

  126. YANG JC, Ohe Y, Chiu CH, Ou X, et al
    Osimertinib plus selumetinib in EGFR-mutated, non-small cell lung cancer after progression on EGFR-TKIs: A Phase 1b, open-label, multicenter trial (TATTON Part B).
    Clin Cancer Res. 2022 May 26. pii: 699247. doi: 10.1158/1078-0432.CCR-21-4329.
    >> Share

  127. KOMMALAPATI A, Mansfield AS
    Trials, tribunals, and opportunities for lung cancer KRASG12C brain metastases.
    Clin Cancer Res. 2022 May 24. pii: 699172. doi: 10.1158/1078-0432.CCR-22-1137.
    >> Share

  128. FRIZZIERO M, Kilgour E, Simpson KL, Rothwell DG, et al
    Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma.
    Clin Cancer Res. 2022;28:1999-2019.
    >> Share

  129. MOORTHI S, Berger AH
    All about that Ras: Novel fusion drives Ras pathway activation in lung cancer.
    Clin Cancer Res. 2022 May 5. pii: 696314. doi: 10.1158/1078-0432.CCR-22-0736.
    >> Share

  130. TON TGN, Pal N, Trinh H, Mahrus S, et al
    Replication of overall survival, progression-free survival, and overall response in chemotherapy arms of non-small cell lung cancer trials using real-world data.
    Clin Cancer Res. 2022 May 5. pii: 696304. doi: 10.1158/1078-0432.CCR-22-0471.
    >> Share

    April 2022
  131. SONG L, Xiong H, Li J, Liao W, et al
    Correction: Sphingosine Kinase-1 Enhances Resistance to Apoptosis through Activation of PI3K/Akt/NFkappaB Pathway in Human Non-small Cell Lung Cancer.
    Clin Cancer Res. 2022;28:1740.
    >> Share

  132. NAKAJIMA EC, Drezner N, Li X, Mishra-Kalyani PS, et al
    FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.
    Clin Cancer Res. 2022;28:1482-1486.
    >> Share

  133. SABARI JK, Velcheti V, Shimizu K, Strickland MR, et al
    Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data From Patients With KRASG12C-Mutant Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2022 Apr 11. pii: 694212. doi: 10.1158/1078-0432.CCR-22-0383.
    >> Share

  134. DEMETRI GD, De Braud F, Drilon A, Siena S, et al
    Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.
    Clin Cancer Res. 2022;28:1302-1312.
    >> Share

    March 2022
  135. ROSNER S, Spira AI
    Has the Enemy "MET" Its Match? Subgroup Analysis Results from VISION Study.
    Clin Cancer Res. 2022;28:1055-1057.
    >> Share

  136. LE X, Sakai H, Felip E, Veillon R, et al
    Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.
    Clin Cancer Res. 2022;28:1117-1126.
    >> Share

  137. DZIADZIUSZKO R, Peters S, Mok T, Camidge DR, et al
    Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.
    Clin Cancer Res. 2022 Mar 11. pii: 681795. doi: 10.1158/1078-0432.CCR-21-2840.
    >> Share

  138. CHIAPPORI AA, Creelan B, Tanvetyanon T, Gray JE, et al
    Phase I study of taminadenant (PBF509/NIR178), an adenosine 2A receptor antagonist, with or without spartalizumab, in patients with advanced non-small cell lung cancer.
    Clin Cancer Res. 2022 Mar 7. pii: 682078. doi: 10.1158/1078-0432.CCR-21-2742.
    >> Share

  139. HAYASHI H, Sugawara S, Fukuda Y, Fujimoto D, et al
    A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).
    Clin Cancer Res. 2022;28:893-902.
    >> Share

    February 2022
  140. LEE JK, Hazar-Rethinam M, Decker B, Gjoerup O, et al
    The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA.
    Clin Cancer Res. 2022;28:728-737.
    >> Share

  141. MAJEED S, Aparnathi MK, Nixon KCJ, Venkatasubramanian V, et al
    Targeting the ubiquitin-proteasome system using the UBA1 inhibitor TAK-243 is a potential therapeutic strategy for small cell lung cancer.
    Clin Cancer Res. 2022 Feb 14. pii: 1078-0432.CCR-21-0344.
    >> Share

  142. MAJEED S, Aparnathi MK, Nixon KCJ, Venkatasubramanian V, et al
    Targeting the ubiquitin-proteasome system using the UBA1 inhibitor TAK-243 is a potential therapeutic strategy for small cell lung cancer.
    Clin Cancer Res. 2022 Feb 11. pii: 681703. doi: 10.1158/1078-0432.CCR-21-0344.
    >> Share

  143. NAKAJIMA EC, Vellanki PJ, Larkins E, Chatterjee S, et al
    FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma.
    Clin Cancer Res. 2022;28:446-451.
    >> Share

    January 2022
  144. CHOW LQM, Barlesi F, Bertino EM, van den Bent MJ, et al
    ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients With ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.
    Clin Cancer Res. 2022 Jan 28. pii: 1078-0432.CCR-21-1838.
    >> Share

  145. RICCIUTI B, Son J, Okoro JJ, Mira A, et al
    Comparative analysis and isoform-specific therapeutic vulnerabilities of KRAS mutations in non-small cell lung cancer.
    Clin Cancer Res. 2022 Jan 28. pii: 1078-0432.CCR-21-2719.
    >> Share

  146. TULLY KM, Tendler S, Carter LM, Sharma SK, et al
    Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer exhibits antitumor efficacy with low toxicity.
    Clin Cancer Res. 2022 Jan 19. pii: 1078-0432.CCR-21-1533.
    >> Share

  147. SUZUKI S, Yonesaka K, Teramura T, Takehara T, et al
    Correction: KRAS Inhibitor Resistance in MET-Amplified KRAS (G12C) Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms.
    Clin Cancer Res. 2022;28:428.
    >> Share

  148. MATHIEU LN, Larkins E, Akinboro O, Roy P, et al
    FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
    Clin Cancer Res. 2022;28:249-254.
    >> Share

  149. MAJEM M, Goldman JW, John T, Grohe C, et al
    Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer who underwent Adjuvant Osimertinib in the phase III ADAURA trial.
    Clin Cancer Res. 2022 Jan 10. pii: 1078-0432.CCR-21-3530.
    >> Share

  150. GAO Y, Paivinen P, Tripathi S, Domenech-Moreno E, et al
    Inactivation of AMPK Leads to Attenuation of Antigen Presentation and Immune Evasion in Lung Adenocarcinoma.
    Clin Cancer Res. 2022;28:227-237.
    >> Share

  151. LEE JC, Green MD, Huppert LA, Chow C, et al
    The Liver-Immunity Nexus and Cancer Immunotherapy.
    Clin Cancer Res. 2022;28:5-12.
    >> Share

    December 2021
  152. YONESAKA K, Tanizaki J, Maenishi O, Haratani K, et al
    HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2021 Dec 17. pii: 1078-0432.CCR-21-3359.
    >> Share

  153. JIN Y, Chen Y, Tang H, Hubert SM, et al
    Activation of PI3K/AKT pathway is a potential mechanism of treatment resistance in small cell lung cancer.
    Clin Cancer Res. 2021 Dec 17. pii: 1078-0432.CCR-21-1943.
    >> Share

  154. DI NOIA V, Pimpinelli F, Renna D, Barberi V, et al
    Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution.
    Clin Cancer Res. 2021;27:6815-6823.
    >> Share

  155. HANNAN R, Mohamad O, Diaz de Leon A, Manna S, et al
    Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma.
    Clin Cancer Res. 2021;27:6716-6725.
    >> Share

  156. LEE CJ, Schoffski P, Modave E, van Wezel T, et al
    Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib.
    Clin Cancer Res. 2021;27:6737-6748.
    >> Share

    November 2021
  157. XIA L, Mei J, Kang R, Deng S, et al
    Perioperative ctDNA-based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
    Clin Cancer Res. 2021 Nov 29. pii: 1078-0432.CCR-21-3044.
    >> Share

  158. SONG Z, Lv D, Chen SQ, Huang J, et al
    Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial.
    Clin Cancer Res. 2021 Nov 9. pii: 1078-0432.CCR-21-2936.
    >> Share

  159. ZHOU Q, Wu L, Hu P, An T, et al
    A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1/2 study.
    Clin Cancer Res. 2021 Nov 5. pii: 1078-0432.CCR-21-2595.
    >> Share

  160. BISWAS T, Dowlati A, Kunos CA, Pink JJ, et al
    Adding Base Excision Repair Inhibitor TRC102 to standard Pemetrexed-Platinum-Radiation in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Results of a phase I trial.
    Clin Cancer Res. 2021 Nov 5. pii: 1078-0432.CCR-21-2025.
    >> Share

  161. CASARRUBIOS M, Cruz-Bermudez A, Nadal E, Insa A, et al
    Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy.
    Clin Cancer Res. 2021;27:5878-5890.
    >> Share

  162. CHUA KP, Teng YHF, Tan AC, Takano A, et al
    Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities.
    Clin Cancer Res. 2021;27:5939-5950.
    >> Share

    October 2021
  163. MEHTA S, Fiorelli R, Bao X, Pennington-Krygier C, et al
    A Phase 0 Trial of Ceritinib in Patients with Brain Metastases and Recurrent Glioblastoma.
    Clin Cancer Res. 2021 Oct 26. pii: 1078-0432.CCR-21-1096.
    >> Share

  164. GAVRIELATOU N, Liu Y, Vathiotis I, Zugazagoitia J, et al
    Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2021 Oct 22. pii: 1078-0432.CCR-21-2649.
    >> Share

    September 2021
  165. KAWAZOE A, Itahashi K, Yamamoto N, Kotani D, et al
    TAS-116 plus nivolumab in patients with colorectal cancer and other solid tumors: an, open-label, dose-finding, and expansion phase Ib trial (EPOC1704).
    Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-1929.
    >> Share

  166. PORCIUNCULA A, Morgado M, Gupta R, Syrigos K, et al
    Spatial mapping and immunomodulatory role of the OX40/OX40L pathway in human non-small cell lung cancer.
    Clin Cancer Res. 2021 Sep 13. pii: 1078-0432.CCR-21-0987.
    >> Share

    August 2021
  167. SHI J, Wang Z, Zhang J, Xu Y, et al
    Genomic landscape and tumor mutational burden determination of circulating tumor DNA in over 5,000 Chinese lung cancer patients.
    Clin Cancer Res. 2021 Aug 26. pii: 1078-0432.CCR-21-1537.
    >> Share

  168. CAMIDGE DR, Morgensztern D, Heist RS, Barve M, et al
    Phase 1 Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients With Advanced Non-Small Cell Lung Carcinoma.
    Clin Cancer Res. 2021 Aug 23. pii: 1078-0432.CCR-21-0765.
    >> Share

  169. MAITLAND ML, Sachdev JC, Sharma MR, Moreno V, et al
    First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
    Clin Cancer Res. 2021;27:4511-4520.
    >> Share

  170. SUZUKI S, Yonesaka K, Teramura T, Takehara T, et al
    KRAS inhibitor-resistance in MET-amplified KRAS (G12C) non-small cell lung cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms.
    Clin Cancer Res. 2021 Aug 7. pii: 1078-0432.CCR-21-0856.
    >> Share

  171. SUBBIAH V, Gainor JF, Oxnard GR, Tan DSW, et al
    Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial.
    Clin Cancer Res. 2021;27:4160-4167.
    >> Share

  172. KIM SY, Kim SM, Lim S, Lee JY, et al
    Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma.
    Clin Cancer Res. 2021;27:4397-4409.
    >> Share

  173. CONFORTI F, Pala L, Pagan E, Bagnardi V, et al
    Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion.
    Clin Cancer Res. 2021;27:4311-4324.
    >> Share

    July 2021
  174. NAKAGAWA K, Nadal E, Garon EB, Nishio M, et al
    RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-small Cell Lung Cancer.
    Clin Cancer Res. 2021 Jul 22. pii: 1078-0432.CCR-21-0273.
    >> Share

  175. KOCH AL, Vellanki PJ, Drezner N, Li X, et al
    FDA Approval Summary: Osimertinib for adjuvant treatment of surgically resected non-small cell lung cancer, a collaborative Project Orbis review.
    Clin Cancer Res. 2021 Jul 22. pii: 1078-0432.CCR-21-1034.
    >> Share

  176. CHANG JC, Offin M, Falcon C, Brown D, et al
    Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes.
    Clin Cancer Res. 2021;27:4066-4076.
    >> Share

  177. LUO J, Martucci VL, Quandt Z, Groha S, et al
    Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer.
    Clin Cancer Res. 2021 Jul 8. pii: 1078-0432.CCR-21-0921.
    >> Share

  178. FOSTER JH, Voss SD, Hall DC, Minard CG, et al
    Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912).
    Clin Cancer Res. 2021;27:3543-3548.
    >> Share

    June 2021
  179. WEISS SA, Djureinovic D, Jessel S, Krykbaeva I, et al
    A phase I study of APX005M and cabiralizumab with/without nivolumab in patients with melanoma, kidney cancer or non-small cell lung cancer resistant to anti-PD-(L)1.
    Clin Cancer Res. 2021 Jun 17. pii: 1078-0432.CCR-21-0903.
    >> Share

  180. RAGHAV K, Hwang H, Jacome AA, Bhang E, et al
    Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary.
    Clin Cancer Res. 2021;27:3414-3421.
    >> Share

  181. GARON EB, Spira AI, Johnson M, Bazhenova L, et al
    A phase 1b open-label, multicenter study of inhaled DV281, a TLR9 agonist, in combination with nivolumab in patients with advanced or metastatic non-small cell lung cancer.
    Clin Cancer Res. 2021 Jun 9. pii: 1078-0432.CCR-21-0263.
    >> Share

  182. LEWIS CD, Singh AK, Hsu FF, Thotala D, et al
    Targeting a Radiosensitizing Antibody-Drug Conjugate to a Radiation-Inducible Antigen.
    Clin Cancer Res. 2021;27:3224-3233.
    >> Share

  183. COMPTE M, Harwood SL, Erce-Llamazares A, Tapia-Galisteo A, et al
    An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.
    Clin Cancer Res. 2021;27:3167-3177.
    >> Share

    May 2021
  184. KIM J, Bradford D, Larkins E, Pai-Scherf LH, et al
    FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid cancers with RET gene mutations or fusions.
    Clin Cancer Res. 2021 May 27. pii: 1078-0432.CCR-21-0967.
    >> Share

  185. CORTOT AB, Madroszyk-Flandin A, Giroux Leprieur E, Molinier O, et al
    First-line Afatinib plus Cetuximab for EGFR-mutant Non-small-cell Lung Cancer: Results from the Randomized Phase 2 IFCT-1503 ACE-Lung Study.
    Clin Cancer Res. 2021 May 24. pii: 1078-0432.CCR-20-4604.
    >> Share

  186. CHOUDHURY NJ, Schoenfeld AJ, Flynn J, Falcon CJ, et al
    Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions.
    Clin Cancer Res. 2021;27:2920-2927.
    >> Share

  187. BYERS LA, Bentsion D, Gans S, Penkov K, et al
    Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naive Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study.
    Clin Cancer Res. 2021 May 4. pii: 1078-0432.CCR-20-4259.
    >> Share

  188. JONES GD, Caso R, Tan KS, Mastrogiacomo B, et al
    KRAS (G12C) Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma.
    Clin Cancer Res. 2021;27:2604-2612.
    >> Share

    April 2021
  189. CHEN K, Nie Y, Park S, Zhang K, et al
    Development and Validation of Machine Learning-based Model for the Prediction of Malignancy in Multiple Pulmonary Nodules: Analysis from Multicentric Cohorts.
    Clin Cancer Res. 2021;27:2255-2265.
    >> Share

  190. OEHL K, Vrugt B, Wagner U, Kirschner MB, et al
    Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma.
    Clin Cancer Res. 2021;27:2277-2291.
    >> Share

  191. DREYFUSS AD, Goia D, Shoniyozov K, Shewale SV, et al
    A Novel Mouse Model of Radiation-Induced Cardiac Injury Reveals Biological and Radiological Biomarkers of Cardiac Dysfunction with Potential Clinical Relevance.
    Clin Cancer Res. 2021;27:2266-2276.
    >> Share

  192. SHAFIQUE M, Fisher TL, Evans EE, Leonard JE, et al
    A Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2021 Apr 5. pii: 1078-0432.CCR-20-4792.
    >> Share

    March 2021
  193. BERTINO EM, Gentzler RD, Clifford S, Kolesar J, et al
    Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903).
    Clin Cancer Res. 2021;27:1604-1611.
    >> Share

  194. SI H, Kuziora M, Quinn KJ, Helman E, et al
    A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.
    Clin Cancer Res. 2021;27:1631-1640.
    >> Share

  195. SITTHIDEATPHAIBOON P, Galan-Cobo A, Negrao MV, Qu X, et al
    STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition.
    Clin Cancer Res. 2021;27:1720-1733.
    >> Share

  196. AGGARWAL C, Thompson JC, Carpenter EL
    Plasma Tumor Mutation Burden and Response to Pembrolizumab-Response.
    Clin Cancer Res. 2021;27:1581.
    >> Share

  197. XUE Z, Guo X, Wen J, Cai W, et al
    Plasma Tumor Mutation Burden and Response to Pembrolizumab-Letter.
    Clin Cancer Res. 2021;27:1580.
    >> Share

  198. ESTRADA-BERNAL A, Le AT, Doak AE, Tirunagaru VG, et al
    Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes.
    Clin Cancer Res. 2021;27:1463-1475.
    >> Share

  199. HACKENG WM, Dreijerink KMA, de Leng WWJ, Morsink FHM, et al
    Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool.
    Clin Cancer Res. 2021;27:1341-1350.
    >> Share

  200. ZHOU C, Wang Y, Zhao J, Chen G, et al
    Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy.
    Clin Cancer Res. 2021;27:1296-1304.
    >> Share

  201. TANIMOTO A, Matsumoto S, Takeuchi S, Arai S, et al
    Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression.
    Clin Cancer Res. 2021;27:1410-1420.
    >> Share

    February 2021
  202. GARON EB
    Osimertinib plus Ramucirumab: The Best of Both Worlds?
    Clin Cancer Res. 2021;27:905-907.
    >> Share

  203. SKOULIDIS F
    Transcription Strikes Back: Clinical Utility of Lung Adenocarcinoma Subtypes.
    Clin Cancer Res. 2021;27:913-915.
    >> Share

  204. HELLMANN MD, Janne PA, Opyrchal M, Hafez N, et al
    Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy.
    Clin Cancer Res. 2021;27:1019-1028.
    >> Share

  205. TAN Y, Sementino E, Cheung M, Peri S, et al
    Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma.
    Clin Cancer Res. 2021;27:1200-1213.
    >> Share

  206. DAEMEN A, Cooper JE, Myrta S, Wongchenko MJ, et al
    Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma.
    Clin Cancer Res. 2021;27:1162-1173.
    >> Share

  207. AI X, Cui J, Zhang J, Chen R, et al
    Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641).
    Clin Cancer Res. 2021;27:704-712.
    >> Share

  208. GUO R, Offin M, Brannon AR, Chang J, et al
    MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance.
    Clin Cancer Res. 2021;27:799-806.
    >> Share

    January 2021
  209. RAHMA OE, Reuss JE, Giobbie-Hurder A, Shoja E Razavi G, et al
    Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors.
    Clin Cancer Res. 2021;27:485-491.
    >> Share

  210. GEIGER T, Beck L, Harel M, Yu S, et al
    Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ-Specificity and Treatment Resistance.
    Clin Cancer Res. 2021 Jan 14. pii: 1078-0432.CCR-20-3752.
    >> Share

  211. DEUTSCH E, Chargari C, Weichselbaum RR, Levy A, et al
    Drug-Radiotherapy Combination Trial Developments-Response.
    Clin Cancer Res. 2021;27:356.
    >> Share

  212. EVANS JR, Cuneo KC, Lawrence TS
    Drug-Radiotherapy Combination Trial Developments-Letter.
    Clin Cancer Res. 2021;27:355.
    >> Share

  213. COLCLOUGH N, Chen K, Johnstrom P, Strittmatter N, et al
    Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs.
    Clin Cancer Res. 2021;27:189-201.
    >> Share

    November 2020
  214. BRADFORD D, Larkins E, Mushti SL, Rodriguez L, et al
    FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid cancers with RET Gene Mutations or Fusions.
    Clin Cancer Res. 2020 Nov 25. pii: 1078-0432.CCR-20-3558.
    >> Share

    April 2020
  215. EGUREN-SANTAMARIA I, Sanmamed MF, Goldberg SB, Kluger HM, et al
    PD-1/PD-L1 blockers in NSCLC brain metastases: challenging paradigms and clinical practice.
    Clin Cancer Res. 2020 Apr 30. pii: 1078-0432.CCR-20-0798.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016